Código QR (código de barras bidimensional)

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase II CONTROL trial investigated antidiarrheal prophy...

Fuld beskrivelse

Na minha lista:
Principais autores: Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2023-02-01
Serier:Breast
Fag:
Neratinib
Tyrosine kinase inhibitor
HER2-positive
Breast cancer
Early stage
Diarrhea prophylaxis
Online adgang:http://www.sciencedirect.com/science/article/pii/S0960977622001953
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker